1. Vencevičienė L, Butrimienė I, Vencevičius R, Sadauskienė E, Kasiulevičius V, Šapoka V. Factors associated with bone mineral density loss in patients with spondyloarthropathies: A 4-year follow-up study. Medicina 2015;51:272-79. [DOI:10.1016/j.medici.2015.08.001]

2. Liu H, Chen J, Zhuang XJ, Chen LC. Disease progression associated with low bone mass in axial spondyloarthropathy patients. Arch Osteoporos 2021;16:65. [DOI:10.1007/s11657-021-00928-3]

3. Carette S, Graham D, Little H, Rubenstein J, Rosen P. The natural disease course of ankylosing spondylitis. Arthritis Rheum 1983;26:186-90. [DOI:10.1002/art.1780260210]

4. Tan S, Wang R, Ward MM. Syndesmophyte growth in ankylosing spondylitis. Curr Opin Rheumatol 2015;27:326-32. [DOI:10.1097/BOR.0000000000000179]

5. Gran JT, Skomsvoll JF. The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol 1997;36:766-71. [DOI:10.1093/rheumatology/36.7.766]

6. Zilber K, Gorenberg M, Rimar D, Boulman N, Kaly L, Rozenbaum M, et al. Radionuclide Methods in the Diagnosis of Sacroiliitis in Patients with Spondyloarthritis: An Update. Rambam Maimonides Med J 2016;7:e0037. [DOI:10.5041/RMMJ.10264]

7. Melchior J, Azraq Y, Chary-Valckenaere I, Rat A-C, Reignac M, Texeira P, et al. Radiography, abdominal CT and MRI compared with sacroiliac joint CT in diagnosis of structural sacroiliitis. Europ j radiol 2017;95:169-76. [DOI:10.1016/j.ejrad.2017.08.004]

8. Reid IR. Vitamin D effect on bone mineral density and fractures. Endocrinol Metabol Clin 2017;46:935-45. [DOI:10.1016/j.ecl.2017.07.005]

9. Kriegel MA, Manson JE, Costenbader KH, editors. Does vitamin D affect risk of developing autoimmune disease?: a systematic review. Semin Arthritis Rheum 2011;40512-531.

10. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chemist Biol 2014;21:319-29. [DOI:10.1016/j.chembiol.2013.12.016]

11. Vargas-Alarcón G, Londono J, Hernandez-Pacheco G, Pacheco-Tena C, Castillo E, Cardiel M, et al. Effect of HLA-B and HLA-DR genes on susceptibility to and severity of spondyloarthropathies in Mexican patients. Ann Rheum Dis 2002;61:714-7. [DOI:10.1136/ard.61.8.714]

12. Khan MA. HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995;7:263-9. [DOI:10.1097/00002281-199507000-00001]

13. de Castro JL. The pathogenetic role of HLA-B27 in chronic arthritis. Curr Opin Rheumatol 1998;10:59-66. [DOI:10.1016/S0952-7915(98)80033-2]

14. Nicknam MH, Ganjalikhani Hakemi M, Jamshidi AR, Khosravi F, Amirkhani A, Narouinejad M, et al. Association between HLA-b27 antigen and ankylosing spondylitis in Iranian patients. Hakim Res J 2005;8:29-34. [In Persian]

15. Donnelly S, Doyle D, Denton A, Rolfe I, McCloskey E, Spector T. Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 1994;53:117-21. [DOI:10.1136/ard.53.2.117]

16. Singh A, Bronson W, Walker SE, Allen SH. Relative value of femoral and lumbar bone mineral density assessments in patients with ankylosing spondylitis. Southern Med J 1995;88:939-43. [DOI:10.1097/00007611-199509000-00010]

17. Briot K, Etcheto A, Miceli-Richard C, Dougados M, Roux C. Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Rheumatology (Oxford) 2016;55:335-42. [DOI:10.1093/rheumatology/kev332]

18. Ulu MA, Çevik R, Dilek B. Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis. Rheumatol Int 2013;33:1705-11. [DOI:10.1007/s00296-012-2632-9]

19. Lange U, Kluge A, Strunk J, Teichmann J, Bachmann G. Ankylosing spondylitis and bone mineral density-what is the ideal tool for measurement? Rheumatol Int 2005;26:115-20. [DOI:10.1007/s00296-004-0515-4]

20. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. Rheumatol Int 2005;32:1290-8.

21. Briot K, Durnez A, Paternotte S, Miceli-Richard C, Dougados M, Roux C. Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort. Ann Rheum Dis 2013;72:1914-9. [DOI:10.1136/annrheumdis-2012-201845]

22. Akgöl G, Kamanlı A, Ozgocmen S. Evidence for inflammation-induced bone loss in non-radiographic axial spondyloarthritis. Rheumatology (Oxford) 2014;53:497-501. [DOI:10.1093/rheumatology/ket385]

23. Mullaji A, Upadhyay S, Ho E. Bone mineral density in ankylosing spondylitis. DEXA comparison of control subjects with mild and advanced cases. J Bone Joint Surg Bri 1994;76:660-5. [DOI:10.1302/0301-620X.76B4.8027159]

24. Baek H, Kang S, Lee Y, Shin K, Lee E, Yoo C, et al. Osteopenia in men with mild and severe ankylosing spondylitis. Rheumatol Int 2005;26:30-4. [DOI:10.1007/s00296-004-0516-3]

25. Obermayer-Pietsch BM, Lange U, Tauber G, Frühauf G, Fahrleitner A, Dobnig H, et al. Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int 2003;14:995-1000. [DOI:10.1007/s00198-003-1501-5]

26. Kim H-R, Kim H-Y, Lee S-H. Elevated serum levels of soluble receptor activator of nuclear factors-κB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 2006;45:1197-200. [DOI:10.1093/rheumatology/kel072]

27. Mermerci Başkan B, Pekin Doğan Y, Sivas F, Bodur H, Özoran K. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int 2010;30:375-81. [DOI:10.1007/s00296-009-0975-7]

28. Grazio S, Kusić Z, Cvijetić S, Grubišić F, Balenović A, Nemčić T, et al. Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study. Rheumatol Int 2012;32:2801-8. [DOI:10.1007/s00296-011-2066-9]

29. Jun J-B, Joo K-B, Her M-Y, Kim T-H, Bae S-C, Yoo D-H, et al. Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 2006;33:1637-41.

30. Vasdev V, Bhakuni D, Garg MK, Narayanan K, Jain R, Chadha D. Bone mineral density in young males with ankylosing spondylitis. Int J Rhe Dis 2011;14:68-73. [DOI:10.1111/j.1756-185X.2010.01577.x]

31. Toussirot E, Michel F, Wendling D. Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology (Oxford) 2001;40:882-8. [DOI:10.1093/rheumatology/40.8.882]

32. Speden DJ, Calin AI, Ring FJ, Bhalla AK. Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 2002;29:516-21.

33. Prieto-Alhambra D, Muñoz-Ortego J, De Vries F, Vosse D, Arden N, Bowness P, et al. Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study. Osteoporosis Int 2015;26:85-91. [DOI:10.1007/s00198-014-2939-3]

34. Kang KY, Lee KY, Kwok S-K, Ju JH, Park K-S, Hong YS, et al. The change of bone mineral density according to treatment agents in patients with ankylosing spondylitis. Joint Bone Spine 2011;78:188-93. [DOI:10.1016/j.jbspin.2010.05.010]

35. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor α treatment. Ann Rheum Dis 2005;64:1137-40. [DOI:10.1136/ard.2004.028670]

36. Allali F, Breban M, Porcher R, Maillefert J, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003;62:347-9. [DOI:10.1136/ard.62.4.347]

37. Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol 2008;35:855-61.

38. Kirveskari J, Kellner H, Wuorela M, Soini H, Frankenberger B, Leirisalo-Repo M, et al. False-negative serological HLA-B27 typing results may be due to altered antigenic epitopes and can be detected by polymerase chain reaction. Br J Rheumatol 1997;36:185-9. [DOI:10.1093/rheumatology/36.2.185]

39. Kelley WN, Harris ED, Ruddy S, Sledge CB, Eds. Textbook of rheumatology. 3rd ed. Philadelphia: WB Saunders; 1989. P.2144.

40. Ren E, Koh W, Sim D, Boey M, Wee G, Chan S. Possible protective role of HLA‐B* 2706 for ankylosing spondylitis. Tissue Antigens 1997;49:67-9. [DOI:10.1111/j.1399-0039.1997.tb02713.x]

41. González S, Martínez-Borra J, López-Larrea C. Immunogenetics, HLA-B27 and spondyloarthropathies. Curr Opin Rheumatol 1999;11:257-64. [DOI:10.1097/00002281-199907000-00006]

42. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67. https://doi.org/10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G [DOI:10.1002/1529-0131(199801)41:13.0.CO;2-G]

43. Brown M, Wordsworth P. Predisposing factors to spondyloarthropathies. Curr Opinin Rheumatol 1997;9:306-14. [DOI:10.1097/00002281-199707000-00006]